Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.44 |
| ▸ | CPB1 | P15086 | 5/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.38 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13619853 | 0.83 | CPB2 (0.39) | CPB1CPB2CPA1KMOGAA | |
| SCHEMBL12627666 | 0.82 | APLNR (0.40) | APLNRCPB1CPB2KMOAGBL2 | |
| SCHEMBL13619841 | 0.79 | APLNR (0.38) | APLNRKMOGAAMAPK1CXCR1 | |
| SCHEMBL13619836 | 0.78 | CXCR1 (0.37) | APLNRGAAMAPK1CXCR1CXCR2 | |
| SCHEMBL17765226 | 0.77 | APLNR (0.51) | APLNRKMOPTGS1PTGS2MAPK1 | |
| SCHEMBL12627635 | 0.77 | CPA1 (0.43) | APLNRCPB1CPB2CPA1PTGS1 | |
| SCHEMBL10518849 | 0.75 | CYP2C19 (0.49) | CPB1CPB2GAASMN1; SMN2NPSR1 | |
| SCHEMBL12627608 | 0.75 | APLNR (0.38) | APLNRCPB1CPB2CPA1 | |
| SCHEMBL17765315 | 0.73 | APLNR (0.46) | APLNRKMOMAPK1FFAR2RXFP1 | |
| SCHEMBL4782064 | 0.72 | APLNR (0.47) | APLNRKMOMAPK1FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009134616-A2 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | EIF2AK2, HAVCR2, HDGF | APLNR 3713/4885CPB1 837/4885CPB2 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.